Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0055 | 0.1589 | 0.1589 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.1615 | 0.1615 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0039 | 0.1014 | 0.1014 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0012 | 0.0023 | 0.0023 |
Entamoeba histolytica | hexokinase 1 | 0.0171 | 0.5847 | 1 |
Schistosoma mansoni | jun-related protein | 0.0073 | 0.2279 | 0.3897 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.1615 | 0.1615 |
Echinococcus granulosus | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Brugia malayi | bZIP transcription factor family protein | 0.009 | 0.2895 | 0.2895 |
Brugia malayi | Hexokinase family protein | 0.0171 | 0.5847 | 0.5847 |
Brugia malayi | Hexokinase family protein | 0.0053 | 0.1536 | 0.1536 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.009 | 0.2895 | 0.2895 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.1615 | 0.1615 |
Echinococcus multilocularis | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Plasmodium falciparum | hexokinase | 0.0171 | 0.5847 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.1615 | 0.2762 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0043 | 0.1182 | 0.2022 |
Loa Loa (eye worm) | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Echinococcus granulosus | hexokinase type 2 | 0.0171 | 0.5847 | 0.5847 |
Schistosoma mansoni | hexokinase | 0.0171 | 0.5847 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.0171 | 0.5847 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0171 | 0.5847 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.1615 | 0.1615 |
Loa Loa (eye worm) | hexokinase type II | 0.0171 | 0.5847 | 0.5847 |
Trypanosoma brucei | hexokinase | 0.0171 | 0.5847 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0043 | 0.1182 | 0.2022 |
Onchocerca volvulus | 0.0171 | 0.5847 | 1 | |
Toxoplasma gondii | hexokinase | 0.0171 | 0.5847 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0037 | 0.0954 | 0.5 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0012 | 0.0023 | 0.0023 |
Brugia malayi | Iron-sulfur cluster assembly accessory protein | 0.0058 | 0.1724 | 0.1724 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.1615 | 0.2762 |
Brugia malayi | hypothetical protein | 0.0039 | 0.1014 | 0.1014 |
Entamoeba histolytica | hexokinase 2 | 0.0171 | 0.5847 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0073 | 0.2279 | 0.3897 |
Trypanosoma brucei | hexokinase | 0.0171 | 0.5847 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Trypanosoma brucei | hexokinase, putative | 0.0171 | 0.5847 | 0.5 |
Echinococcus granulosus | voltage gated potassium channel | 0.0012 | 0.0023 | 0.0023 |
Brugia malayi | hexokinase type II | 0.0055 | 0.1589 | 0.1589 |
Echinococcus multilocularis | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Onchocerca volvulus | 0.0171 | 0.5847 | 1 | |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0039 | 0.1014 | 0.1734 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.1615 | 0.1615 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.004 | 0.105 | 0.105 |
Schistosoma mansoni | survival motor neuron protein | 0.0058 | 0.1724 | 0.2949 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0039 | 0.1014 | 0.1014 |
Leishmania major | hexokinase, putative | 0.0171 | 0.5847 | 0.5 |
Onchocerca volvulus | 0.0071 | 0.2188 | 0.3743 | |
Echinococcus multilocularis | hexokinase type 2 | 0.0171 | 0.5847 | 0.5847 |
Echinococcus granulosus | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Leishmania major | hexokinase, putative | 0.0171 | 0.5847 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.0171 | 0.5847 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.2805 | 0.2805 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0023 | 0.0023 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.1615 | 0.1615 |
Onchocerca volvulus | 0.0171 | 0.5847 | 1 | |
Loa Loa (eye worm) | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Brugia malayi | Hexokinase family protein | 0.0108 | 0.3521 | 0.3521 |
Trypanosoma cruzi | hexokinase, putative | 0.0171 | 0.5847 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0053 | 0.1536 | 0.1536 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0859 | 0.0859 |
Echinococcus granulosus | jun protein | 0.009 | 0.2895 | 0.2895 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0037 | 0.0954 | 0.5 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.004 | 0.105 | 0.105 |
Onchocerca volvulus | 0.0058 | 0.1724 | 0.2949 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.1615 | 0.2762 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0012 | 0.0023 | 0.0023 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.004 | 0.105 | 0.105 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0012 | 0.0023 | 0.0023 |
Schistosoma mansoni | hypothetical protein | 0.0058 | 0.1724 | 0.2949 |
Onchocerca volvulus | 0.0108 | 0.3521 | 0.6021 | |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.009 | 0.2895 | 0.2895 |
Loa Loa (eye worm) | hypothetical protein | 0.0055 | 0.1589 | 0.1589 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0012 | 0.0023 | 0.0039 |
Schistosoma mansoni | hypothetical protein | 0.0039 | 0.1014 | 0.1734 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.3862 | 0.3862 |
Echinococcus multilocularis | jun protein | 0.009 | 0.2895 | 0.2895 |
Brugia malayi | hypothetical protein | 0.0071 | 0.2188 | 0.2188 |
Loa Loa (eye worm) | hexokinase | 0.0108 | 0.3521 | 0.3521 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.004 | 0.105 | 0.105 |
Onchocerca volvulus | Hexokinase homolog | 0.0108 | 0.3521 | 0.6021 |
Echinococcus multilocularis | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0012 | 0.0023 | 0.0039 |
Brugia malayi | hexokinase | 0.0171 | 0.5847 | 0.5847 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.